Relugolix

Overview

Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC 50 =0.33 nM) and monkey receptor ( IC 50 =0.32 nM) compared with TAK-013 ( HY-100209 ). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.

Application

Products | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Prostate Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GnRH Receptor

Product Information

• Catalog No.: HY-16474
• CAS No.: 737789-87-6
• Molecular Formula: C29H27F2N7O5S
• Molecular Weight: 623.63
• Purity: 99.53%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.83 mg/mL (1.33 mM); Clear solution
• Availability: In-stock

Source

Original product source